Spark Therapeutics (ONCE) Stock Rating Reaffirmed by Royal Bank of Canada

Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “outperform” rating reissued by analysts at Royal Bank of Canada in a report issued on Thursday. They presently have a $65.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 23.69% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Wedbush upgraded Spark Therapeutics from an “underperform” rating to a “neutral” rating and decreased their target price for the stock from $65.00 to $50.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. SunTrust Banks boosted their target price on Spark Therapeutics to $113.00 and gave the stock a “buy” rating in a research note on Thursday, January 4th. BMO Capital Markets boosted their target price on Spark Therapeutics from $64.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. ValuEngine cut Spark Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Leerink Swann cut Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 target price for the company. in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $73.45.

Spark Therapeutics (ONCE) traded up $1.52 during mid-day trading on Thursday, reaching $52.55. The company had a trading volume of 625,950 shares, compared to its average volume of 712,063. The stock has a market capitalization of $1,944.61, a PE ratio of -7.28 and a beta of 3.02. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $91.75.

In other Spark Therapeutics news, CFO Stephen W. Webster sold 10,000 shares of Spark Therapeutics stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total transaction of $701,400.00. Following the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $876,750. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the transaction, the insider now directly owns 215,000 shares in the company, valued at approximately $15,333,800. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,518 shares of company stock worth $2,882,554. 7.30% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Spark Therapeutics by 3.2% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 342 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the period. California Public Employees Retirement System increased its holdings in shares of Spark Therapeutics by 2.1% in the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock valued at $2,336,000 after purchasing an additional 800 shares during the period. Aperio Group LLC increased its holdings in shares of Spark Therapeutics by 29.2% in the fourth quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 898 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Spark Therapeutics by 5.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 21,428 shares of the biotechnology company’s stock valued at $1,102,000 after purchasing an additional 1,013 shares during the period. 94.57% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics (ONCE) Stock Rating Reaffirmed by Royal Bank of Canada” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/11/spark-therapeutics-once-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply